Genevieve
Genevieve Almouzni, Paris FR
Patent application number | Description | Published |
---|---|---|
20150038496 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES - The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1a silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma. | 02-05-2015 |
Genevieve Almouzni, Neuilly Sur Seine FR
Patent application number | Description | Published |
---|---|---|
20130149320 | Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer - The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for treating cancer. | 06-13-2013 |
Genevieve Almouzni, Neuilly/seine FR
Patent application number | Description | Published |
---|---|---|
20110003706 | PROLIFERATION MARKERS IN CLINICAL PRACTICE AND THEIR USE FOR BREAST CANCER PROGNOSIS OR DIAGNOSIS - A method for assessing the proliferative state of cells in a human or non-human biological sample uses Chromatin Assembly Factor-1 (CAF-1) subunits as proliferation markers. The method can be used for breast cancer prognosis or diagnosis, and monitoring tumor response in therapy. | 01-06-2011 |
Genevieve Baute, Saint Medard D'Eyrans FR
Patent application number | Description | Published |
---|---|---|
20090081260 | NATURALLY RESORBABLE POLYACRYLAMIDE GEL, PRODUCTION PROCESS AND USES - A biodegradable polyacrylamide gel that is obtained from acrylamide monomers that are connected to one another by at least one amino acid includes at least one acryloylated amine or acryloylated amide group, or by at least one amino acid oligopeptide that comprises at least one acryloylated amine or acryloylated amide group. The process for synthesis of this gel and its uses are also disclosed. | 03-26-2009 |
Genevieve Blandiaux, Trooz BE
Patent application number | Description | Published |
---|---|---|
20080251105 | Cleaning Compositions Comprising Hydrogen Peroxide - The present invention is directed to cleaning compositions and cleaning systems comprising an anionic surfactant, a nonionic surfactant, lactic acid, hydrogen peroxide and water. In various embodiments, the compositions may further comprise an amphoteric or pseudo-cationic surfactant, an alcohol and a glycol ether solvent. The present invention is also directed to cleaning systems comprising the compositions in contained within a bottle having a nozzle and a spray pump dispenser, as well as methods for removing stain and/or soil from a surface. | 10-16-2008 |
Genevieve Bonnechere, Awans BE
Patent application number | Description | Published |
---|---|---|
20110226293 | ALKALINE CLEANING COMPOSITIONS - A cleaning composition comprising: (i) a buffering system comprising a strong base and an organic acid; (ii) an alkanolamine; (iii) at least one surfactant chosen from a zwitterionic surfactant, a non-ionic surfactant, an ionic surfactant and mixtures thereof; and (iv) an organic solvent chosen from lower alkanols, glycol ethers and diethers, and mixtures thereof; wherein the pH of the composition is about 9 to about 13. These alkaline cleaning compositions are useful to remove burnt-on and/or baked-on soil deposits and grease. | 09-22-2011 |
Genevieve Bonnechere-Delstanche, Awans BE
Patent application number | Description | Published |
---|---|---|
20130085094 | CLEANING COMPOSITION WITH IMPROVED STAIN REMOVAL - The invention relates to a cleaning composition with improved stain removal. The alkaline composition contains a hydrolysable dispersing polymer which is selected from carboxylated fructans and one or more biodegradable aminocarboxylate chelating agents. | 04-04-2013 |
Genevieve Cerf, Groton Long Point, CT US
Patent application number | Description | Published |
---|---|---|
20110135070 | SYNCHRONIZING VOICEMAIL AMONG MULTIPLE CLIENT ACCESS POINTS - A set of servers connect to a group of voicemail systems and to a group of client access points. The set of servers may receive a request to perform a transaction relating to a voicemail mailbox of a particular voicemail system; cause the transaction to be performed with regard to the voicemail mailbox of the particular voicemail system; and receive a notification that the transaction was performed with regard to the voicemail mailbox of the particular voicemail system. The set of servers may perform synchronization processes to synchronize the client access points with regard to the transaction that was performed with regard to the voicemail mailbox of the particular voicemail system, where each of the client access points contains a same view of the voicemail mailbox as a result of the synchronization processes. | 06-09-2011 |
20110136474 | AGGREGATED MULTI-NUMBER VISUAL VOICEMAIL SERVER - A system, in which a server is connected to a group of voicemail servers, is provided. A first voicemail server provides voicemail services to landline telephone devices. A second voicemail server provides voicemail services to wireless telephone devices. The server receives information regarding a first voicemail intended for a user of a user device, receives information regarding a second voicemail intended for the user of the user device, aggregates the information regarding the first voicemail and the information regarding the second voicemail as aggregated information, and sends the aggregated information to the user device. | 06-09-2011 |
Genevieve Estenne-Bouhtou, Paris FR
Patent application number | Description | Published |
---|---|---|
20120071536 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to N-[(2-aza-bicyclo[2.2.1]hex-1-yl)-aryl-methyl]-benzamide derivatives of the general formula (I) where: R is a hydrogen atom or a (C | 03-22-2012 |
Genevieve Estenne-Bouhtou, Chevilly-Larue FR
Patent application number | Description | Published |
---|---|---|
20090258899 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The disclosure relates to a compound of formula (I): | 10-15-2009 |
20100022548 | USE OF N-HETEROCYCLYLMETHYLBENZAMIDES IN THERAPEUTICS - The invention relates to use of compositions in therapeutics containing a compound having general formula (I): | 01-28-2010 |
20100234424 | DERIVATIVES OF N-PHENYL(PIPERIDINE-2-YL) METHYL BENZAMIDE PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME IN THERAPEUTICS - Compounds of formula (I) as defined herein: | 09-16-2010 |
20100267766 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The disclosure relates to a compound of formula (I): | 10-21-2010 |
Genevieve Garand, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20120089933 | CONTENT CONFIGURATION FOR DEVICE PLATFORMS - The present technology includes a digital content authoring tool for authoring digital content without the need to understand or access computer code. The present technology further includes creating digital content that can be modified with animation of assets. Each animation can be controlled by an action, and the actions can be tied to a time axis for execution. By relating actions to a time axis, animations based on the actions can be more easily viewed and reviewed. In some embodiments, the system can clear a page of all but a selected asset so that it may be more easily worked with. | 04-12-2012 |
Genevieve Glastre Lemaitre, Marcoussis FR
Patent application number | Description | Published |
---|---|---|
20130301985 | MONOLITHIC INTEGRATED STRUCTURE COMPRISING A BURIED HETEROSTRUCTURE SEMICONDUCTOR OPTICAL AMPLIFIER AND A PHOTODETECTOR - A monolithic integrated structure comprising a buried heterostructure semiconductor optical amplifier and a deep ridge optical receiver comprising such structure are disclosed. | 11-14-2013 |
Genevieve Le Bas, Paris FR
Patent application number | Description | Published |
---|---|---|
20090285867 | METHOD FOR EXTEMPORANEOUS AND REVERSIBLE CONCENTRATION OF LIPOSOMES - The invention concerns a method for extemporaneous and reversible concentration of liposomes, the mixed liposome-cyclodextrin aggregates obtainable by the method, and uses thereof in the pharmaceutical, diagnostic and cosmetic field. | 11-19-2009 |
Genevieve Lee, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20090235239 | BUILD SYSTEM REDIRECT - Embodiments may provide a makefile interposer, which enables a makefile to be used for building software for different platforms without modifying the makefile. In some embodiments, the interposer intercepts the commands run by makefile and automatically interposes the correct library files, dependencies, paths, and other information used by make to build the program for a particular platform. Additionally, calls that the invoked tools themselves make are intercepted and the interposer may redirect them to the platform-specific tools or file system locations including redirecting file descriptors. In some instances, when a tool is called that is not in the platform, the interposer may also fall back on the other system tools. | 09-17-2009 |
20130283235 | BUILD SYSTEM REDIRECT - Embodiments may provide a makefile interposer, which enables a makefile to be used for building software for different platforms without modifying the makefile. In some embodiments, the interposer intercepts the commands run by makefile and automatically interposes the correct library files, dependencies, paths, and other information used by make to build the program for a particular platform. Additionally, calls that the invoked tools themselves make are intercepted and the interposer may redirect them to the platform-specific tools or file system locations including redirecting file descriptors. In some instances, when a tool is called that is not in the platform, the interposer may also fall back on the other system tools. | 10-24-2013 |
Genevieve Libeau, Montpellier FR
Patent application number | Description | Published |
---|---|---|
20090136544 | Interfering RNAs Targeting the Morbillivirus Nucleoprotein Gene - The invention relates to interfering RNAs (siRNAs, shRNAs or pre-miRNAs) directed against conserved regions of the mRNA of the N gene encoding the morbillivirus nucleoprotein. The invention also relates to the use of said interfering RNAs for the production of medicaments for use in the treatment or prevention of a morbillivirus infection. | 05-28-2009 |
Genevieve Losonsky, Phoenix, MD US
Patent application number | Description | Published |
---|---|---|
20100098708 | METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS - The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k | 04-22-2010 |
20110008329 | Methods of Treating RSV Infections And Related Conditions - The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient. | 01-13-2011 |
20110158985 | METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS - The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k | 06-30-2011 |
Genevieve Marcelin, New York, NY US
Patent application number | Description | Published |
---|---|---|
20140294854 | TARGET DIRECTED TO ADIPOCYTES, METHODS AND ASSAYS FOR TREATMENT OF OBESITY - The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject. | 10-02-2014 |
Genevieve Martin, Berkel-Enschot NL
Patent application number | Description | Published |
---|---|---|
20130100665 | LIGHTING DEVICE - A lighting device ( | 04-25-2013 |
Genevieve Martin, Loos FR
Patent application number | Description | Published |
---|---|---|
20090060905 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity - The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences. | 03-05-2009 |
Genevieve Nguyen, Paris FR
Patent application number | Description | Published |
---|---|---|
20160018416 | NEW DUAL BIOMARKER OF NEURODEGENERATION AND OF NEUROREGENERATION - A new dual biomarker of neurodegeneration and of neuroregeneration | 01-21-2016 |
Genevieve Nonet, Berkeley, CA US
Patent application number | Description | Published |
---|---|---|
20080292620 | PRLR-Specific Antibody and Uses Thereof - PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 11-27-2008 |
20110150760 | PRLR-Specific Antibody and Uses Thereof - PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 06-23-2011 |
20150175705 | PRLR-SPECIFIC ANTIBODY AND USES THEREOF - PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 06-25-2015 |
Genevieve Pacana, Glendale, CA US
Patent application number | Description | Published |
---|---|---|
20100121693 | DIGITAL ADVERTISING DISPLAY APPARATUS AND METHOD FOR PROVIDING CONTROLLED CONTENT TO A DIGITAL ADVERTISING DISPLAY - Various embodiments of this invention disclose a digital advertising display apparatus and method of providing controlled content to a digital advertising display. The digital advertising display may be located in a public, private, or retail space. The content provided may be an advertisement that is related to a specific product, informational, educational, or artistic. The content is delivered through wireless communications. | 05-13-2010 |
Genevieve Patenaude, Edinburgh GB
Patent application number | Description | Published |
---|---|---|
20110101239 | REMOTE SENSING SYSTEM - An airborne the multi-spectral lidar instrument emits and/or detects radiation from target vegetation to assess the condition of the foliage. Time of flight analysis at multiple wavelengths permits three dimensional measurements to discriminate material at different heights, from ground to top of canopy. Radiation at 531 nm (emission and detection, vertically resolved) is used to measure de-epoxidation of the xanthophyll pigments (used for PRI), and also for stimulation of fluorescence. Radiation at 550 and/or 570 or 571 nm (emission and detection, vertically resolved) serves as a reference waveband unaffected by the de-epoxidation (used for PRI). Radiation at 690 and 740 nm (Detection only, no height resolution) or other lines for chlorophyll fluorescence, optionally using Fraunhofer/Oxygen wavelength windows and/or time gating to improve SNR. Wavelengths of 860 and 1200 nm, or similar (emission and detection, vertically resolved) are applied to measurement of water absorption and estimation of NDWI. Results are combined with known available radiation to estimate primary productivity. | 05-05-2011 |
Genevieve Pratviel, Toulouse FR
Patent application number | Description | Published |
---|---|---|
20090203546 | SOLID SUPPORTS FUNCTIONALIZED WITH PHOSPHORUS-CONTAINING DENDRIMERS, PROCESS FOR PREPARING THEM AND USES THEREOF - The present invention relates to solid supports functionalized with phosphorus-containing dendrimers, to a process for preparing them, to their use for preparing biochips and to the uses of these biochips, in particular for immobilizing molecules of interest, especially biological molecules of interest such as nucleic acids, polypeptides, lipids and proteins. | 08-13-2009 |
Genevieve Robert-Reitman, Montecito, CA US
Patent application number | Description | Published |
---|---|---|
20090212669 | STORAGE UNIT WITH EXTENSION MECHANISM - A storage unit comprises an arm assembly that can be stored inside the unit and extended along a range of positions outside the unit and a moveable panel which conceals the interior of the storage unit frame coupled with the storage unit frame by a connector. The storage unit can be integrated into an article of furniture such as a headboard or a chair. A four-bar linkage assembly can be used to connect the moveable panel to the storage unit frame and can permit the panel to remain substantially parallel to the frame along its range of motion. | 08-27-2009 |
Genevieve Rougon, Marseille FR
Patent application number | Description | Published |
---|---|---|
20090105131 | USE OF POLY-ALPHA2,8-SIALIC ACID MIMETIC PEPTIDES TO MODULATE NCAM FUNCTIONS - The invention relates to the use of a peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, said peptide comprising a B epitope of a poly-α2,8 sialic acid attached to NCAM, which is recognized by an anti-poly-α2,8 sialic acid (PSA) antibody, for the preparation of a medicament for modulating NCAM functions, to be administered for the prevention and/or the treatment of neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer. | 04-23-2009 |
Genevieve Schubetzer, Colomiers FR
Genevieve Spik, Marcq En Baroeul FR
Patent application number | Description | Published |
---|---|---|
20110092411 | RECOMBINANT LACTOFERRINS, METHODS OF PRODUCTION FROM PLANTS AND USES THEREOF - The invention concerns the use of a recombinant nucleotide sequence containing a DNAc coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by said DNAc, in particular a transcription promoter and terminator identified by the plant cell transcription machinery, to transform plant cells in order to obtain, from these cells, or plants obtained therefrom, lactoferrin or derived proteins. | 04-21-2011 |
Genevieve Stratos, Sullivan'S Island, SC US
Patent application number | Description | Published |
---|---|---|
20150330064 | WATER DISPENSER DECONTAMINATION DEVICE - A water dispenser includes a decontamination device. The dispenser has a plurality of channels that communicate with a water supply. The channels are intermittently exposed to pathogen killing radiation during operation of the water dispenser. | 11-19-2015 |
Genevieve Sztrubel, Ramat Hasharon IL
Patent application number | Description | Published |
---|---|---|
20150208934 | Method And Apparatus For The Detection Of Neural Tissue - The invention relates to a method and apparatus for neural tissue detection carried out using the Neural Tissue Detector (NTD), which is the apparatus that embodies the hardware aspect of the invention. The NTD enables neural tissue detection by stimulating a small tissue area and by measuring possible occurrences of induced response from neural tissue, if neural tissue is present in said small stimulated tissue area. The information gathered by the measurement provides a real-time assessment of the nature of the tissue which is targeted by the NTD. The invention is applicable to all types of neural tissues, including motor, and/or sensory and/or other types of neural tissues. The invention offers particular advantages in robot based surgical procedures or intravascular catheter based procedures but can also be used for manual surgery, according to different specific embodiments. | 07-30-2015 |
Geneviève Almouzni, Neuilly Sur Seine FR
Patent application number | Description | Published |
---|---|---|
20120046190 | HP1ALPHA AS A PROGNOSTIC MARKER IN HUMAN CANCER - The present invention provides a prognostic marker in human cancer, HP1α, a high expression thereof being associated with a poor prognosis. The present invention further provides a method for diagnosing a cancer in a subject, HP1α a being specifically overexpressed in tumoral cells. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy and a method for monitoring the response of a subject affected with a cancer to a treatment. | 02-23-2012 |
Geneviève Bossy, Amberieu En Bugey FR
Patent application number | Description | Published |
---|---|---|
20130084598 | Method for Detecting Clusters of Biological Particles - The invention relates to a method for detecting clusters of biological particles ( | 04-04-2013 |
Geneviève Bossy, Amberieu En Bugey FR
Patent application number | Description | Published |
---|---|---|
20130084598 | Method for Detecting Clusters of Biological Particles - The invention relates to a method for detecting clusters of biological particles ( | 04-04-2013 |
Geneviève Bourdy, Ramonville Saint Agne FR
Patent application number | Description | Published |
---|---|---|
20140011868 | Use of Simalikalactone E as an Anticancer Agent - The invention relates to Simalikalactone E (SkE) to be used for preventing and/or treating cancers. | 01-09-2014 |
Geneviève Bourdy, Ramonville Saint Agne FR
Patent application number | Description | Published |
---|---|---|
20120149767 | Connection Device for a Submersible Connector - The invention relates to a device ( | 06-14-2012 |
Geneviève Choquet-Kastylevsky, Francheville FR
Patent application number | Description | Published |
---|---|---|
20110293636 | Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer. | 12-01-2011 |
20120129200 | PRODEFENSIN-A6 ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer. | 05-24-2012 |
20130171173 | METHOD FOR PRONGF ASSAY FOR IN VITRO DIAGNOSIS OF CANCER IN PARTICULAR BREAST, THYROID OR LUNG CANCER AND THERAPEUTIC USE OF PRONGF - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer. | 07-04-2013 |
Geneviève Dijoux, Paris FR
Patent application number | Description | Published |
---|---|---|
20150281152 | METHOD OF CONSTRUCTING A MESSAGE BY MEANS OF A TERMINAL - One embodiment comprises obtaining an identification of at least one multimedia content and at least one destination user; constructing a message by a challenge definition module installed on a terminal on the basis of at least one interaction with a sender user. The construction may comprise (a) producing metadata defining, in association with the multimedia content, both a challenge for presenting to the destination user and also an expected response to the challenge, the metadata combining the information required for executing the challenge on at least one terminal of the destination user; (b) inserting the metadata and an identifier in the message, the identifier identifying the terminal of the destination user of the message; and (c) using a telecommunications network to send the message and data giving access to the multimedia content to a server for relaying the metadata and the multimedia content to the terminal of the destination user. | 10-01-2015 |
Geneviève Estenne-Bouhtou, Paris FR
Patent application number | Description | Published |
---|---|---|
20120029027 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME - The invention relates to a compound of the general formula (I), where: R is a hydrogen atom or a group selected from the (C | 02-02-2012 |
Geneviève Guedeney, Manosque FR
Patent application number | Description | Published |
---|---|---|
20110212502 | [NiFe]-Hydrogenases Having an Improved Resistance to Dioxygen, Process for Obtaining Them and Their Applications - The invention relates to [NiFe]-hydrogenases having an improved resistance to dioxygen, said [NiFe]-hydrogenases may be obtained by:—providing an initial polynucleotide comprising a sequence encoding a large subunit of a [NiFe]-hydrogenase, said large subunit comprising the following peptide motifs: L1: RGXE, wherein X=L, I, F, V or M L2: [R/K]X | 09-01-2011 |
Geneviève Gueguen-Dorbes, Paris FR
Patent application number | Description | Published |
---|---|---|
20130273049 | ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA - The present invention relates to the use a Robo1-Fc recombinant protein for treating cancer, in particular hepatocarcinoma. | 10-17-2013 |
Geneviève Gueguen-Dorbes, Paris FR
Patent application number | Description | Published |
---|---|---|
20130273049 | ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA - The present invention relates to the use a Robo1-Fc recombinant protein for treating cancer, in particular hepatocarcinoma. | 10-17-2013 |
Geneviève Inchauspe, Lyon FR
Patent application number | Description | Published |
---|---|---|
20080241259 | Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof - The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: | 10-02-2008 |
20090075879 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, and a peptide D having at least the amino acid sequence of SEQ ID No 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 03-19-2009 |
20090087449 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 04-02-2009 |
20090104188 | ANTI-HEPATITIS C VIRUS ANTIBODY AND USES THEREOF - Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation. | 04-23-2009 |
20090155772 | Method for detecting nanbv associated seroconversion - The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention. | 06-18-2009 |
20090186046 | Hepatitis C Virus Non Structural Fusion Protein - The present invention relates to an isolated fusion protein comprising at least three NS polypeptides originating from a hepatitis C virus which are configured in said fusion protein in an order which is distinct of the order in which they appear in the native configuration. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof for treating or preventing HCV infections, HCV-associated diseases and pathologic conditions as well as a method of inducing or stimulating an immune response against HCV in a host organism. | 07-23-2009 |
20100008941 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5 | 01-14-2010 |
20110020398 | Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus - The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods. | 01-27-2011 |
20120039938 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application. | 02-16-2012 |
20130011435 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 01-10-2013 |
20130164250 | METHOD FOR PRODUCTION OF BIORESORBABLE MICROPARTICLES, MICROPARTICLES THUS OBTAINED AND USE THEREOF - Nonlamellar bioresorbable microparticles to which protein substances are bonded, and a method for preparing the microparticles, comprising: (i) preparing the microparticles from at least one bioresorbable polymer without stabilizer and without surfactant; and (ii) bonding the protein substances to the microparticles obtained in step (i) without surfactant. | 06-27-2013 |
Geneviève Inchauspe, Lyon FR
Patent application number | Description | Published |
---|---|---|
20110020398 | Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus - The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods. | 01-27-2011 |
20120251569 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 10-04-2012 |
20130011435 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 01-10-2013 |
Geneviève Loussouarn, Clichy FR
Patent application number | Description | Published |
---|---|---|
20090215837 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 08-27-2009 |
20100105741 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 04-29-2010 |
20130131095 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 05-23-2013 |
Geneviève Loussouarn, Clichy FR
Patent application number | Description | Published |
---|---|---|
20100105741 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 04-29-2010 |
Geneviève Pourroy, Schiltigheim FR
Patent application number | Description | Published |
---|---|---|
20140308628 | METAL MATERIALS HAVING A SURFACE LAYER OF CALCIUM PHOSPHATE, AND METHODS FOR PREPARING SAME - The present invention relates to a multi-layer material comprising a metal or metal alloy substrate, the metal or alloy substrate being coated with an intermediate layer comprising at least one ceramic or crystalline, or partially crystalline, structure, including a metal or a metal alloy, said intermediate layer being coated with a layer of calcium phosphate having a cellular nanometric structure, and uses thereof. | 10-16-2014 |
Geneviève Renauld-Mongenie, Chaponost FR
Patent application number | Description | Published |
---|---|---|
20100184639 | NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC OF THE NEISSERIA GENUS PATHOGENIC STRAINS - The invention concerns nucleic acids coding for polypeptides specific of the | 07-22-2010 |
20100330160 | Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 - The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by | 12-30-2010 |
20120156281 | Meningococcal Vaccine Based on Lipooligosaccharide (LOS) and Neisseria Meningitidis Protein - The invention relates to a vaccine against | 06-21-2012 |
Geneviève Renauld-Mongenie, Chaponost FR
Patent application number | Description | Published |
---|---|---|
20090155886 | NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC FOR PATHOGENIC STRAINS OF THE NEISSERIA GENUS - The invention concerns nucleic acids coding for polypeptides specific of the | 06-18-2009 |
20100184639 | NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC OF THE NEISSERIA GENUS PATHOGENIC STRAINS - The invention concerns nucleic acids coding for polypeptides specific of the | 07-22-2010 |
20100330160 | Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 - The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by | 12-30-2010 |